{"id":"somatostatin-analog","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Cholelithiasis"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL265784","moleculeType":"Small molecule","molecularWeight":"1450.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Somatostatin analogs are synthetic derivatives of the natural hormone somatostatin that activate somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells. This activation suppresses the release of various hormones and growth factors, reducing symptoms from hormone excess and slowing proliferation of somatostatin receptor-positive tumors. They are commonly used in neuroendocrine tumors and gastroenteropancreatic neuroendocrine neoplasms.","oneSentence":"Somatostatin analogs bind to somatostatin receptors on neuroendocrine tumor cells and other tissues, inhibiting hormone secretion and slowing tumor growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:46.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors (gastroenteropancreatic and thoracic)"},{"name":"Acromegaly"},{"name":"Variceal bleeding in portal hypertension"},{"name":"Carcinoid syndrome"}]},"trialDetails":[{"nctId":"NCT07037420","phase":"PHASE2","title":"ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-10-28","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT06991738","phase":"PHASE1, PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Thyroid Cancer","enrollment":18},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":"Acromegaly","enrollment":119},{"nctId":"NCT05477576","phase":"PHASE3","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-03-24","conditions":"GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease","enrollment":288},{"nctId":"NCT02270567","phase":"","title":"RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide","status":"ENROLLING_BY_INVITATION","sponsor":"Wren Laboratories LLC","startDate":"2015-02","conditions":"Neuroendocrine Tumor, Carcinoid, Neuroendocrine Carcinoma","enrollment":400},{"nctId":"NCT03000946","phase":"PHASE3","title":"Prevention of Postoperative Pancreatic Fistula by Somatostatin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-15","conditions":"Pancreatic Surgery","enrollment":655},{"nctId":"NCT04329039","phase":"PHASE2, PHASE3","title":"Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-11-17","conditions":"Pancreatic Diseases","enrollment":103},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT04837885","phase":"PHASE2","title":"Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-24","conditions":"Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour","enrollment":23},{"nctId":"NCT03466216","phase":"PHASE1","title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","status":"TERMINATED","sponsor":"Orano Med LLC","startDate":"2018-02-05","conditions":"Neuroendocrine Tumor","enrollment":33},{"nctId":"NCT05153772","phase":"PHASE2","title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orano Med LLC","startDate":"2021-12-21","conditions":"Neuroendocrine Tumors","enrollment":69},{"nctId":"NCT06372652","phase":"PHASE1","title":"A Phase 1 Study of TE-8214 Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Immunwork, Inc.","startDate":"2024-06-18","conditions":"Acromegaly","enrollment":32},{"nctId":"NCT06974344","phase":"PHASE4","title":"Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)","status":"NOT_YET_RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2025-06-01","conditions":"Small-for-Size Syndrome","enrollment":80},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":"Neuroendocrine Tumors","enrollment":51},{"nctId":"NCT04997317","phase":"PHASE1, PHASE2","title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-21","conditions":"Meningioma","enrollment":18},{"nctId":"NCT04464122","phase":"","title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","status":"RECRUITING","sponsor":"University of Roma La Sapienza","startDate":"2020-09-14","conditions":"Neuroendocrine Tumors, Neuroendocrine Neoplasm, Neuroendocrine Tumor Grade 1","enrollment":60},{"nctId":"NCT05249114","phase":"PHASE1","title":"Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-12-28","conditions":"Neuroendocrine Tumors","enrollment":6},{"nctId":"NCT06855095","phase":"PHASE2, PHASE3","title":"Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-06-25","conditions":"Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2","enrollment":39},{"nctId":"NCT02795858","phase":"PHASE2","title":"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-06-14","conditions":"Carcinoid Tumors","enrollment":43},{"nctId":"NCT03789656","phase":"PHASE2","title":"An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2019-03-12","conditions":"Acromegaly","enrollment":47},{"nctId":"NCT01371045","phase":"","title":"Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2011-06","conditions":"Acromegaly","enrollment":""},{"nctId":"NCT04696042","phase":"","title":"Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2021-01-01","conditions":"Neuroendocrine Tumors","enrollment":71},{"nctId":"NCT06456359","phase":"PHASE2","title":"Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2024-12-19","conditions":"Desmoplastic Small Round Cell Tumor, Synovial Sarcoma","enrollment":28},{"nctId":"NCT02489604","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-12","conditions":"Neuroendocrine Tumors","enrollment":70},{"nctId":"NCT05701241","phase":"PHASE4","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-06-28","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":270},{"nctId":"NCT05359146","phase":"EARLY_PHASE1","title":"Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-28","conditions":"Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)","enrollment":16},{"nctId":"NCT01070758","phase":"PHASE4","title":"Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2010-02","conditions":"Congenital Hyperinsulinism","enrollment":3},{"nctId":"NCT03377660","phase":"","title":"Resection of the Esophagus and Subsequent Weight Loss","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2018-01-01","conditions":"Esophageal Cancer, Weight Gain, Eating Behavior","enrollment":30},{"nctId":"NCT06240039","phase":"NA","title":"Direct Versus Indirect Effect of Amino Acids on Hepatokines","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-02","conditions":"Non-Alcoholic Fatty Liver Disease, Obesity","enrollment":30},{"nctId":"NCT02859064","phase":"PHASE2","title":"Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2017-07-28","conditions":"Neuroendocrine Tumors, Gastrointestinal Neoplasms, Carcinoid Tumors","enrollment":6},{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT02384122","phase":"PHASE3","title":"Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-09","conditions":"Angiodysplasia, Vascular Malformations, Gastrointestinal Hemorrhage","enrollment":62},{"nctId":"NCT05184231","phase":"","title":"Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China","status":"WITHDRAWN","sponsor":"Ipsen","startDate":"2023-02-13","conditions":"Acromegaly","enrollment":""},{"nctId":"NCT02335580","phase":"","title":"Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2014-12","conditions":"Liver Cirrhosis, Portal Vein, Venous Thrombosis","enrollment":475},{"nctId":"NCT02152124","phase":"","title":"Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-06-01","conditions":"Acromegaly","enrollment":21},{"nctId":"NCT03478358","phase":"PHASE1","title":"Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-04-30","conditions":"Neuroendocrine Tumors","enrollment":60},{"nctId":"NCT02685709","phase":"PHASE3","title":"Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly","status":"COMPLETED","sponsor":"Chiasma, Inc.","startDate":"2016-02","conditions":"Acromegaly","enrollment":146},{"nctId":"NCT04672876","phase":"PHASE2","title":"Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-01","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT02749227","phase":"PHASE2","title":"Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors","status":"TERMINATED","sponsor":"Columbia University","startDate":"2017-07-10","conditions":"Pituitary Tumor, ACTH-producing Pituitary Tumour","enrollment":4},{"nctId":"NCT04034745","phase":"","title":"Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain","status":"WITHDRAWN","sponsor":"Andrew Hendifar, MD","startDate":"2020-10","conditions":"Pancreatic Cancer, Neuroendocrine Tumors, Cachexia; Cancer","enrollment":""},{"nctId":"NCT00446082","phase":"PHASE1","title":"Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-06","conditions":"Carcinoid Tumor, Acromegaly","enrollment":85},{"nctId":"NCT00447499","phase":"PHASE3","title":"Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel","status":"COMPLETED","sponsor":"Ipsen","startDate":"2007-04","conditions":"Acromegaly","enrollment":59},{"nctId":"NCT04557137","phase":"","title":"Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2020-09-01","conditions":"Neuroendocrine Tumors (NET) Health Related Qualito of Life (HRQoL)","enrollment":100},{"nctId":"NCT04129255","phase":"PHASE2","title":"Octreotide LAR in the Induction of Immunologic Response in NENs Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2017-06-28","conditions":"Neuroendocrine Tumors","enrollment":34},{"nctId":"NCT04039516","phase":"PHASE2","title":"Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy","status":"UNKNOWN","sponsor":"King's College Hospital NHS Trust","startDate":"2020-10","conditions":"Carcinoid Heart Disease, Carcinoid Syndrome, Carcinoid Tumor","enrollment":20},{"nctId":"NCT01670110","phase":"PHASE2","title":"Pasireotide LAR in Severe Polycystic Liver Disease","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-08","conditions":"Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease","enrollment":48},{"nctId":"NCT00092287","phase":"PHASE3","title":"Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","status":"TERMINATED","sponsor":"Ipsen","startDate":"2004-07","conditions":"Malignant Carcinoid Syndrome","enrollment":4},{"nctId":"NCT04154241","phase":"NA","title":"Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2020-03-10","conditions":"Neuroendocrine Tumors","enrollment":50},{"nctId":"NCT01865760","phase":"NA","title":"Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2013-06","conditions":"Obesity, Hypoglycemia, Surgery","enrollment":33},{"nctId":"NCT04138342","phase":"PHASE1","title":"Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2019-09-15","conditions":"Breast Cancer, Skin Cancer, Skin Diseases","enrollment":30},{"nctId":"NCT03774680","phase":"PHASE1","title":"Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer","status":"UNKNOWN","sponsor":"Ahmed A. H. Abdellatif","startDate":"2020-02-01","conditions":"Colon Cancer, Colo-rectal Cancer","enrollment":30},{"nctId":"NCT01732406","phase":"","title":"Acromegaly Treatment Quality of Life Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-01","conditions":"Acromegaly","enrollment":126},{"nctId":"NCT02705651","phase":"PHASE3","title":"Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2019-12","conditions":"Pancreatic Neuroendocrine Tumors in MEN1","enrollment":180},{"nctId":"NCT03812939","phase":"","title":"Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-01-01","conditions":"Gastric NET","enrollment":30},{"nctId":"NCT00500227","phase":"","title":"Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery","status":"COMPLETED","sponsor":"Ipsen","startDate":"2007-09","conditions":"Acromegaly","enrollment":55},{"nctId":"NCT03629847","phase":"PHASE1, PHASE2","title":"Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2012-12","conditions":"Neuroendocrine Tumors","enrollment":30},{"nctId":"NCT02705313","phase":"","title":"EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx","status":"APPROVED_FOR_MARKETING","sponsor":"Advanced Accelerator Applications","startDate":"","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT01677910","phase":"PHASE3","title":"TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2013-01-08","conditions":"Carcinoid Syndrome","enrollment":135},{"nctId":"NCT02217800","phase":"PHASE2","title":"The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2013-11","conditions":"Acromegaly","enrollment":8},{"nctId":"NCT01372618","phase":"PHASE1, PHASE2","title":"Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2011-06","conditions":"Ductal Carcinoma in Situ","enrollment":9},{"nctId":"NCT02351128","phase":"PHASE2","title":"Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2015-04","conditions":"Carcinoma, Merkel Cell","enrollment":35},{"nctId":"NCT03308682","phase":"PHASE1","title":"177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-04-30","conditions":"Neuroendocrine Tumors","enrollment":30},{"nctId":"NCT01412424","phase":"PHASE3","title":"Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly","status":"COMPLETED","sponsor":"Chiasma, Inc.","startDate":"2012-03","conditions":"Acromegaly","enrollment":155},{"nctId":"NCT00600886","phase":"PHASE3","title":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-02-11","conditions":"Acromegaly","enrollment":358},{"nctId":"NCT00376064","phase":"PHASE4","title":"Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":"Acromegaly","enrollment":20},{"nctId":"NCT01618513","phase":"PHASE4","title":"Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-06","conditions":"Acromegaly","enrollment":84},{"nctId":"NCT02967666","phase":"PHASE1","title":"Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2016-11","conditions":"Tuberculosis, Pulmonary","enrollment":30},{"nctId":"NCT01620138","phase":"PHASE2, PHASE3","title":"Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2010-03","conditions":"Non-functioning Pituitary Adenomas, Prolactinomas","enrollment":21},{"nctId":"NCT02111044","phase":"PHASE2","title":"Phase II Study With ITF2984 in Acromegalic Patients","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2014-04","conditions":"Acromegaly","enrollment":48},{"nctId":"NCT01755182","phase":"PHASE3","title":"Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors","status":"TERMINATED","sponsor":"National Cancer Institute, Naples","startDate":"2013-07","conditions":"Neuroendocrine Tumors","enrollment":1},{"nctId":"NCT01723748","phase":"NA","title":"Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-12","conditions":"Acromegaly, Metabolic Diseases","enrollment":18},{"nctId":"NCT01860742","phase":"PHASE3","title":"Randomized Phase III of PRRT Versus Interferon","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-12","conditions":"Gastro-intestinal Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT00227773","phase":"PHASE2","title":"Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"","conditions":"Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma","enrollment":""},{"nctId":"NCT02012166","phase":"PHASE1","title":"A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT00978211","phase":"PHASE2","title":"DOTA-TOC in Metastasized Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"1997-09","conditions":"Neuroendocrine Tumors","enrollment":1499},{"nctId":"NCT01128192","phase":"PHASE2","title":"Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Robert R. Henry, MD","startDate":"2009-08","conditions":"Hyperglycemia","enrollment":45},{"nctId":"NCT01029275","phase":"NA","title":"Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2005-01","conditions":"Acromegaly","enrollment":89},{"nctId":"NCT00813592","phase":"PHASE2","title":"Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-11","conditions":"Cancer","enrollment":2},{"nctId":"NCT01460706","phase":"PHASE2, PHASE3","title":"Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT","status":"COMPLETED","sponsor":"Turku University Hospital","startDate":"2011-10","conditions":"Glioma","enrollment":30},{"nctId":"NCT00510224","phase":"PHASE2","title":"Sandostatin for Patients With Androgen Independent Prostate Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2007-07","conditions":"Prostate Cancer","enrollment":13},{"nctId":"NCT00765323","phase":"PHASE3","title":"Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly","status":"TERMINATED","sponsor":"Endo Pharmaceuticals","startDate":"2008-09","conditions":"Acromegaly","enrollment":169},{"nctId":"NCT00690430","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Symptomatic Refractory Resistant Carcinoid Disease","enrollment":186},{"nctId":"NCT01895296","phase":"PHASE2","title":"Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2008-09","conditions":"Postoperative Dumping Syndrome","enrollment":9},{"nctId":"NCT01871844","phase":"PHASE1","title":"ITF2984 Repeated Doses Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2012-01","conditions":"Healthy Male Volunteers","enrollment":46},{"nctId":"NCT00652379","phase":"NA","title":"Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2008-06","conditions":"Acromegaly, Insulin Resistance, Impaired Glucose Tolerance","enrollment":18},{"nctId":"NCT01203306","phase":"PHASE2","title":"Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2006-01","conditions":"Neuroendocrine Carcinomas","enrollment":42},{"nctId":"NCT01188733","phase":"PHASE1, PHASE2","title":"Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"1998-06","conditions":"Cirrhosis, Portal Hypertension, Esophageal Varices","enrollment":39},{"nctId":"NCT00569738","phase":"","title":"Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2008-12","conditions":"Neuroendocrine Tumor","enrollment":20},{"nctId":"NCT00331188","phase":"PHASE3","title":"Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding","status":"COMPLETED","sponsor":"Debiovision","startDate":"2006-05","conditions":"Esophageal Varices, Portal Hypertension, Gastric Varices","enrollment":70},{"nctId":"NCT00703079","phase":"","title":"Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly","status":"COMPLETED","sponsor":"Federico II University","startDate":"1997-01","conditions":"Acromegaly","enrollment":100},{"nctId":"NCT00595140","phase":"PHASE4","title":"Acute Application of Pegvisomant and Octreotide in Acromegaly","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-01","conditions":"Acromegaly","enrollment":10},{"nctId":"NCT00642720","phase":"PHASE4","title":"Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2006-10","conditions":"Quality of Life, Acromegaly","enrollment":20},{"nctId":"NCT00004327","phase":"PHASE2","title":"Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1995-01","conditions":"Hereditary Hemorrhagic Telangiectasia, Ectasia","enrollment":8}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"FLATULENCE"},{"count":2,"reaction":"NAUSEA"},{"count":1,"reaction":"5-HYDROXYINDOLACETIC ACID INCREASED"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BLOOD POTASSIUM DECREASED"},{"count":1,"reaction":"DEFAECATION URGENCY"},{"count":1,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":1823,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lanreotide","octreotide","sandostatin","somatuline","Arm A"],"phase":"marketed","status":"active","brandName":"Somatostatin analog","genericName":"Somatostatin analog","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Somatostatin analogs bind to somatostatin receptors on neuroendocrine tumor cells and other tissues, inhibiting hormone secretion and slowing tumor growth. Used for Neuroendocrine tumors (gastroenteropancreatic and thoracic), Acromegaly, Variceal bleeding in portal hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}